Integrating muti-omics data to identify tissue-specific DNA methylation biomarkers for cancer risk

Yaohua Yang,Yaxin Chen,Shuai Xu,Xingyi Guo,Guochong Jia,Jie Ping,Xiang Shu,Tianying Zhao,Fangcheng Yuan,Gang Wang,Yufang Xie,Hang Ci,Hongmo Liu,Yawen Qi,Yongjun Liu,Dan Liu,Weimin Li,Fei Ye,Xiao-Ou Shu,Wei Zheng,Li Li,Qiuyin Cai,Jirong Long

DOI: https://doi.org/10.1038/s41467-024-50404-y

2024-07-18

Abstract:The relationship between tissue-specific DNA methylation and cancer risk remains inadequately elucidated. Leveraging resources from the Genotype-Tissue Expression consortium, here we develop genetic models to predict DNA methylation at CpG sites across the genome for seven tissues and apply these models to genome-wide association study data of corresponding cancers, namely breast, colorectal, renal cell, lung, ovarian, prostate, and testicular germ cell cancers. At Bonferroni-corrected P < 0.05, we identify 4248 CpGs that are significantly associated with cancer risk, of which 95.4% (4052) are specific to a particular cancer type. Notably, 92 CpGs within 55 putative novel loci retain significant associations with cancer risk after conditioning on proximal signals identified by genome-wide association studies. Integrative multi-omics analyses reveal 854 CpG-gene-cancer trios, suggesting that DNA methylation at 309 distinct CpGs might influence cancer risk through regulating the expression of 205 unique cis-genes. These findings substantially advance our understanding of the interplay between genetics, epigenetics, and gene expression in cancer etiology.